Andrew Arno - 01 Jul 2024 Form 4 Insider Report for Oncocyte Corp (OCX)

Reporting relationship: Director
Issuer ticker: OCX
Reported as of: 01 Jul 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jul 2024, 21:00:09 UTC
Prior SEC filing: 22 May 2024
Next SEC filing: 08 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Andrew Arno

Key filing fact

Andrew Arno filed Form 4 for Oncocyte Corp (OCX) on 03 Jul 2024.

Key facts

This page summarizes Andrew Arno's Form 4 filing for Oncocyte Corp (OCX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jul 2024, 21:00.

Change

Previous filing in this sequence was filed on 22 May 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OCX transaction Derivative

Option to Purchase Common Stock

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 01 Jul 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $2.95
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.